Anika Therapeutics Inc (NASDAQ:ANIK) — Market Cap & Net Worth
Market Cap & Net Worth: Anika Therapeutics Inc (ANIK)
Anika Therapeutics Inc (NASDAQ:ANIK) has a market capitalization of $191.87 Million ($191.87 Million) as of June 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16784 globally and #3924 in its home market, demonstrating a -3.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anika Therapeutics Inc's stock price $14.42 by its total outstanding shares 13305624 (13.31 Million). Review ANIK total liabilities to assess the company's total debt and financial obligations.
Anika Therapeutics Inc Market Cap History: 2015 to 2026
Anika Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $507.74 Million to $191.87 Million (-7.91% CAGR).
Index Memberships
Anika Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #468 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1657 of 3165 |
Weight: Anika Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anika Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anika Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.13x
Anika Therapeutics Inc's market cap is 1.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $651.44 Million | $103.38 Million | $32.55 Million | 6.30x | 20.02x |
| 2017 | $717.31 Million | $113.42 Million | $31.82 Million | 6.32x | 22.55x |
| 2018 | $447.20 Million | $105.56 Million | $18.72 Million | 4.24x | 23.89x |
| 2019 | $689.90 Million | $114.61 Million | $27.19 Million | 6.02x | 25.37x |
| 2020 | $602.21 Million | $130.46 Million | -$23.98 Million | 4.62x | N/A |
| 2021 | $476.74 Million | $147.79 Million | $4.13 Million | 3.23x | 115.32x |
| 2022 | $393.85 Million | $156.24 Million | -$14.86 Million | 2.52x | N/A |
| 2023 | $301.51 Million | $120.79 Million | -$82.67 Million | 2.50x | N/A |
| 2024 | $219.01 Million | $119.91 Million | -$56.38 Million | 1.83x | N/A |
| 2025 | $127.87 Million | $112.82 Million | -$10.88 Million | 1.13x | N/A |
Competitor Companies of ANIK by Market Capitalization
Companies near Anika Therapeutics Inc in the global market cap rankings as of June 20, 2026.
Key companies related to Anika Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
Anika Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Anika Therapeutics Inc's market cap moved from $507.74 Million to $ 191.87 Million, with a yearly change of -7.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $191.87 Million | +50.05% |
| 2025 | $127.87 Million | -41.62% |
| 2024 | $219.01 Million | -27.36% |
| 2023 | $301.51 Million | -23.45% |
| 2022 | $393.85 Million | -17.39% |
| 2021 | $476.74 Million | -20.84% |
| 2020 | $602.21 Million | -12.71% |
| 2019 | $689.90 Million | +54.27% |
| 2018 | $447.20 Million | -37.66% |
| 2017 | $717.31 Million | +10.11% |
| 2016 | $651.44 Million | +28.30% |
| 2015 | $507.74 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of Anika Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $191.87 Million USD |
| MoneyControl | $191.87 Million USD |
| MarketWatch | $191.87 Million USD |
| marketcap.company | $191.87 Million USD |
| Reuters | $191.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more